EZH2 and breast carcinoma: Previous studies have been reported that histone deacetylase inhibitors or EZH2 inhibitors could result in a phenotypic switch from BLBC into ER+ breast cancer, leading to the acquisition of sensitivity to hormone therapy,[16, 36] but the master regulator remained unclear.